周二，Baird对全球持续气道正压通气(CPAP)市场领导者ResMed (NYSE:RMD)的股票启动覆盖，给予"跑赢大市"评级，目标价为$280。 该公司的分析表明，ResMed战略性地定位于从CPAP设备市场渗透率增长中受益，这是一个稳定的中单位数增长市场。 尽管缺乏与竞争对手召回相关的市场份额增长和定价利好，但Baird预计ResMed将保持中单位数到高单位数的收入增长和低双位数到中十几位 ...

Shares of ResMed Inc. RMD inched 0.51% higher to $246.18 Monday, on what proved to be an all-around great trading session for ...

*Insider roster data is derived solely from the last 24 months of Form 3 & Form 4 SEC filings.

A new dose-finding study supported the potential of the carbonic anhydrase inhibitor as an alternative to CPAP machines.

风险批露: 交易股票、外汇、商品、期货、债券、基金等金融工具或加密货币属高风险行为，这些风险包括损失您的部分或全部投资金额，所以交易并非适合所有投资者。加密货币价格极易波动，可能受金融、监管或政治事件等外部因素的影响。保证金交易会 ...

Israel Launches Airstrikes on Hezbollah, Killing at Least 270 in Lebanon It was the deadliest day of Israeli attacks in Lebanon since at least 2006. The Lebanese health ministry said over 1,000 ...

A third of us are unhappy with the quality – and quantity – of our sleep. Is the answer as simple as an early night... every night?